Novo Nordisk received notice from the Food and Drug Administration that its review of denecimig for the treatment of hemophilia A is still ongoing. The FDA hasn't communicated a new timeline for ...
Falling wages. An energy crisis. Growing international conflicts. A losing war. A divisive and increasingly unpopular ...
Shares of Wynn Resorts Ltd. WYNN slid 1.84% to $75.88 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.73% to 7,722.72 and ...
Shares of Nordson Corp. NDSN advanced 1.37% to $333.54 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.73% to 7,722.72 and ...
Digital health-care company iRhythm Holdings provided an update on a cybersecurity incident it disclosed in June, saying certain information about customers was downloaded by unauthorized individuals ...
Shares in the communication services sector rose, lifted by a broad stock rally. Paramount Chief Executive David Ellison said he would rename his combined company Skydance after acquiring Warner Bros.
Voya Financial said Santhosh Keshavan will trade in his chief technology and operations officer title, for that of chief risk and global operating officer, effective Jan. 1. At that time, Rajat Kalia ...
Shares in the technology sector rose on a risk-on session, as the AI buildup marches on. Applied Digital said it has brought an additional 75 megawatts of computing power online at its data center ...
Shares in the financial sector were slightly higher as borrowing costs remained near multidecade highs. Redemption requests for two of Blue Owl Capital's private-credit funds remained well above the ...
Shares of companies in the consumer sector rose following recent losses, despite slower-than-expected U.S. job creation last month. After two straight quarters of falling revenue, Nike said it expects ...
Health-care companies edged lower, as a risk-on mood weighed on the typically defensive sector. Novartis struck a deal valued at up to $7.8 billion to license a messenger RNA drug candidate from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results